Todd Schlesinger, MD, FAAD, FASMS

Because BCC and cSCC have high tumor mutational burdens driven by UV-induced DNA damage, they are particularly well suited to immune checkpoint inhibition.

At AAD 2026, Todd Schlesinger, MD, highlighted how staging frameworks and clinicopathologic features can inform treatment decisions in nonmelanoma skin cancer.

Todd Schlesinger, MD, highlights data supporting red light–activated PDT with 10% ALA gel for superficial basal cell carcinoma, discussing structured treatment protocols and manageable tolerability.

Todd Schlesinger, MD, reviews emerging randomized trial data supporting red light–activated photodynamic therapy with 10% aminolevulinic acid gel and outlines key considerations for patient selection in superficial basal cell carcinoma (sBCC).

Todd Schlesinger, MD, discusses emerging evidence, clearance outcomes, and practical considerations for using red light–based photodynamic therapy as a nonsurgical option in select superficial basal cell carcinoma (BCC) cases.

In the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.

In part 3 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

In part 2 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

In part 1 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

Experts in dermatology discuss treatment considerations for particular patient populations, highlighting the importance of managing adverse events aggressively.

Experts in dermatology discuss the efficacy and safety combining hedgehog pathway inhibitors and immunotherapy as treatment for patients with basal cell carcinoma.

Todd Schlesinger, MD and Emily Ruiz, MD offer advice on forming multidisciplinary relationships for the wholistic study and treatment of basal cell carcinoma.

Emily Ruiz, MD and Todd Schlesinger, MD discuss treatment options for locally advanced basal cell carcinoma, such as immunotherapy and surgery.

Todd Schlesinger, MD, FAAD, outlines his research on newly FDA-approved topical tirbanibulin (Klisyri, Almirall) for treatment of actinic keratosis (AK), as well as compares it to another topical treatment for AK, 5-fluorouracil.